Imatinib Eg

Imatinib, the active ingredient in Imatinib Eg, is a tyrosine kinase inhibitor presented as a oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Eg targets specific tyrosine‑kinase driven malignancies and is employed in the following indications:

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by inhibiting the BCR‑ABL fusion protein. - Gastrointestinal stromal tumor (GIST): blocks KIT‑driven tumor growth, leading to disease control.

Adverse reactions may occur with Imatinib therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent, usually self‑limiting. - Fatigue: generalized tiredness. - Diarrhea: loose stools, may be watery. - Rash: maculopapular skin eruption.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac failure: signs of reduced cardiac output. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: increased pressure in lung arteries. - Tumor lysis syndrome: metabolic disturbances from rapid tumor breakdown.

Before initiating Imatinib, clinicians should consider several safety measures.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac risk. - Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in pregnancy: benefits must outweigh potential fetal risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct light.

Imatinib may interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic levels. - Concomitant use with QT‑prolonging agents (e.g., sotalol): heightened risk of arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., midazolam, cyclosporine): adjust dose as needed. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously. - Vaccines (live attenuated): monitor immune response, consider timing of administration.